Vista Pharmaceuticals has informed that pursuant to the special resolution passed by the members of the Company under Section 62 of the Companies Act, 2013 on 14th October, 2022 and In- principle approval received from BSE on 30.11.2022, and the allotment of warrants dated 14th December 2022, the allotment of 5,33,333 equity shares of Rs 2 in the Company’s Equity Share Capital, on conversion of 5,33,333 Warrants, be and are hereby allotted to the person as mentioned below at a price of Rs 10 per equity shares includes a premium of Rs 8 per share: for which the Board of Directors have accorded their approval, at their meeting held on 30th December, 2023 Commenced at 10.00 PM and Concluded at 10:15 AM.
The above information is a part of company’s filings submitted to BSE.
